Tag Archives: Treatments

Cancer drug treats damaged hearts

Scientists are testing a drug that can mend a broken heart.

Experiments found the medicine, which is usually used to treat cancer, shrank enlarged and diseased hearts back down to near normal size, allowing them to work properly again.

Now the drug is about to be given to human heart patients for the first time.

In the future, it could be used to prevent and treat heart failure – one of the biggest causes of hospital admissions and death.

The drug’s powerful effect could provide a godsend for some of the millions worldwide suffering from heart failure, in which a weakened heart struggles to pump blood around the body.

Caused by heart attacks, high blood pressure and other conditions, more than 750,000 people live with it in the UK alone, with everyday tasks such as eating, dressing and getting out of bed leaving many sufferers breathless and exhausted.

Treatments range from drugs to transplants but with up to 40 per cent of those affected dying within a year of diagnosis, it has a worse survival rate than many cancers.

The human heart

The human heart

The medicine tested belongs to a family of drugs called histone deacetylases, which are already used to treat tumours.

But research from the University of Texas’s Southwestern heart centre shows that they also temper autophagy, a process in which cells eat their own proteins.

Autophagy allows cells to tidy up unwanted debris. But when it gets out of control, too many vital parts are eaten and the cells die.

In hearts, this can further damage those which are already diseased.

The researchers gave the drug to mice with high levels of autophagy and enlarged hearts that could fail, with incredible results.

Joseph Hill, the heart centre’s chief of cardiology, said: ‘The heart decreased back to near its normal size, and heart function that had previously been declining went back to normal. That is a powerful observation where disease regression, not just disease prevention, was seen.’

He hopes the drug could be used to repair hearts damaged by heart attacks and other forms of disease.

Dr Hill told the Daily Mail: ‘There is a huge need for new treatments for heart failure.

‘The final common pathway for most types of heart disease, high blood pressure, heart attacks or valve disease is heart failure and it is sky-rocketing.’


He is about to start small, preliminary tests on heart patients. If successful, larger-scale trials will follow.

The tests that led to the breakthrough began ‘decades ago’ on yeast, said the researchers, but only now does it seem likely it can be adapted to the human heart.

Dr Hill said: ‘This is one of those exciting, but rare, examples where an important finding made originally in yeast moved into mouse models and is soon moving to humans.’

The approach is one of several being explored around the world.

The British Heart Foundation wants to raise £50million within five years to fund research into repairing hearts.

Launching the appeal earlier this year, Professor Peter Weissberg, the BHF’s medical director, said: ‘Scientifically, mending human hearts is an achievable goal and we really could make recovering from a heart attack as simple as getting over a broken leg.’

Last night, Professor Jeremy Pearson, the charity’s associated medical director, said: ‘This is an intriguing study which suggests that an anti-cancer drug can, unexpectedly, be beneficial in heart failure – a condition which urgently needs new medicines to help treat it.’

Prostate cancer news

Scientists have identified an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory.

The findings offer promising leads for research towards new treatments.

In the new study, scientists at Imperial College London found that a protein called FUS inhibits the growth of prostate cancer cells in the laboratory, and activates pathways that lead to cell suicide.

The researchers also looked for the FUS protein in samples from prostate cancer patients. They found that in patients with high levels of FUS, the cancer was less aggressive and was less likely to spread to the bone. Higher levels of FUS also correlated with longer survival. The results suggest that FUS might be a useful marker that can give doctors an indication of how aggressive a tumour will be.

prostate cancer

Prostate cancer

“These findings suggest that FUS might be able to suppress tumour growth and stop it from spreading to other parts of the body where it can be deadly. It”s early stages yet but if further studies confirm these findings, then FUS might be a promising target for future therapies,” said Dr Charlotte Bevan, senior author of the study, from the Department of Surgery and Cancer at Imperial College London.

Prostate cancer depends on male hormones to progress as these hormones stimulate the cancer cells to divide, enabling the tumour to grow. Treatments that reduce hormone levels or stop them from working are initially effective, but eventually the tumour stops responding to this treatment and becomes more aggressive.


Dr Bevan and her team began by exposing prostate cancer cells to male hormones and looking at how the levels of different proteins changed. They discovered that the hormones made the cells produce less of the FUS protein, and examined further whether FUS might influence cell growth by inserting extra copies of the gene for FUS into cells grown in culture. They found that making the cells produce more FUS led to a reduction in the number of cancer cells in the dish.

The findings have been published in the journal Cancer Research.